Final SEC Judgement on Ferrone:

https://www.sec.gov/litigation/litreleases/2017/lr23891.htm

IMYN revoked:

http://www.sec.gov/litigation/admin/2015/34-75419.pdf

IMYN SEC Admin Proceeding:

http://www.sec.gov/litigation/admin/2015/34-74779.pdf

IMYN SEC Suspension:

http://www.sec.gov/litigation/suspensions/2015/34-74398.pdf

Order:

http://www.sec.gov/litigation/suspensions/2015/34-74398-o.pdf

Any news at all on this? No comments since fraud allegations back in August, but their chart shows activity up until eight days ago. Wha'happin?

Jumped out with a small loss this morning, very bad news indeed. May jump back in if the fraud claims are not justified, but I figured I'd jump out with a small loss before it grows into a bigger loss while things get figured out...

IMYN

Bad news!

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=65804001

IMYN looking good. I think this is a great under-recognized play and I'm staying long here for sure...

IMYN

IMYN – Buy Confirmed!!! Ready to Move
American Bulls Trigger first signal things may progress to Dollar Land
http://www.americanbulls.com/StockPage.asp?CompanyTicker=IMYN&MarketTicker=OTC&TYP=S

The recent bullish formation leading to the BUY-IF signal is confirmed today. The market is ready for a new bullish move. It opened today with a gap-up and the day’s activity resulted in a close higher than the open. This is one of our valid confirmation criteria.
We hope that you bought this stock. You should watch the upward gap in the opening, wait a bit, feel the bullish tendency of the market making sure that prices stay over the opening price and then go long. Your benchmark was the opening price of the upward gap.

IMYN has License Approval in Europe
for it's Biopharmaceutical Drug - Immunosyn Corporation has approval from the MHRA to import base material and manufacture it's drug for human use in clinical trials. Immunosyn holds the exclusive license for worldwide marketing rights.

The "Medicines and Healthcare products Regulatory Agency," more commonly known as the MHRA, functions in the United Kingdom on behalf of the European Medicines Agency (EMEA) much like the FDA does in the United States. MHRA regulates which drugs are safe and effective for use in humans to treat specific ailments and conditions. The license approvals currently granted by the MHRA include a "Manufacturer's Authorisation -- Investigational Medicinal Products" (MIA (IMP)) as well as "Manufacturer's / Importer's Licence" (MIA) for manufacturing investigational medicinal products for use in humans for phase I, II and III clinical trials. If a company successfully completes these trials it can apply for a full license to distribute throughout the European Union.

"The fact that it has garnered manufacturing and import approval from the MHRA so rapidly is exciting news," says Stephen D. Ferrone, CEO and President of Immunosyn, "as every milestone we achieve in this process brings us that much closer to producing revenue for our shareholders."

"This is another example whereby Immunosyn's shareholders strongly benefit from our unique relationship with our largest shareholder, Argyll Biotechnologies," stated David Criner, CFO of Immunosyn. "Under the terms of our exclusive license agreement, Argyll Biotechnologies is responsible for all regulatory approvals and clinical trials including those required by the MHRA and FDA together with their associated costs."

Under EMEA requirements, in order to obtain approval to manufacture a drug for use in humans, whether for clinical trials or for general use, an approved manufacturer must be able to demonstrate its ability to comply with the rules governing "Good Manufacturing Practice" (GMP) and apply directly to the MHRA for license approval. Following a series of manufacturing "scale-up" studies, Argyll Biotechnologies entered into an agreement with Biozyme Laboratories. As a result of this agreement, Biozyme applied for and received manufacturing and base materials import approval from MHRA for clinical trials for the Immunosyn Corporation.

NO NEGATIVE SHOWING
n no case was there a negative showing as to a safety issue and in most there was a measurable improvement in a clinical condition
SF-1019 has shown great promise over a wide range of applications relating to conditions of an inflammatory nature such as Multiple Sclerosis (MS), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Reflex Sympathetic Dystrophy Syndrome (RSD or RSDS).

Following a series of toxicity studies in animals, SF-1019 demonstrated a positive safety profile.

Recently, in one of Argyll Biotechnologies’ pre-clinical human studies, a small number of patients were provided with SF-1019 treatments under informed consent (EU) and a compassionate waiver program (US). Information collected from this study extended over a ten month period and included a brief record of clinical progress (if any), together with dose ranging and toxicity data.

A standard battery of blood tests were undertaken pre-treatment and at four, eight and twelve week intervals. In no case was there a negative showing as to a safety issue and in most there was a measurable improvement in a clinical condition. For example, there were no apparent biochemical changes in the blood analysis and no adverse reactions recorded in this group.

Many of the patients who participated in this program continue to receive compassionate treatments of SF-1019.

Science Behind Immunosyn

SF-1019 has also been shown to function
as a vaccine adjuvant for antigens
of both viral and bacterial origin

SF-1019 comprises the platform technology for what Argyll Biotechnologies believes may lead to a new, world class series of Biological Response Modifiers (BMRs) developed from mammalian serum. Argyll Biotechnologies feels this technology represents a cutting edge scientific breakthrough, utilizing some of the many complex compounds and cells generated by the immune systems of living animals in response to viral, bacterial and other stress challenges. The current research medications for a number of neurological conditions, as derived from SF-1019, have demonstrated their ability to create a wide variety of immune responses by targeting both the innate and adaptive immune systems simultaneously.

The basic technology and mechanism of action of SF-1019 were originally discovered by Argyll Biotechnologies’ principal investigator, Professor Kenneth Willeford, of Mississippi State University. Claims in a key patent application, which encompass the SF-1019 molecule and names Dr. Willeford as an inventor, have recently been allowed and are expected to issue. Additional patent protection has also been applied for concerning the manufacturing processes and chemical variations of SF-1019.

SF-1019, as disclosed and described in Argyll Biotechnologies’ published patent applications, comprises a group of novel lipo-peptides which have no direct antimicrobial activity when screened against a variety of gram positive and gram negative bacteria. Nevertheless, in pre-clinical human studies as well as animal studies, SF-1019 demonstrates an ability to abate microbial pathogenesis as presented in Salmonella typhimurium mouse and Pasteurella multocida avian models while also appearing to abate viral pathogenesis as presented in a canine parvovirus study. SF-1019 has also been shown to function as a vaccine adjuvant for antigens of both viral and bacterial origin. In veterinary clinical field trials, it has been shown to be effective against bovine respiratory disease complex (shipping fever), canine parvo viral enteritis, equine West Nile Viral encephalitis, and equine respiratory disease.

Following an initial infection, the adaptive immune system may take days or weeks to react. However as most organisms are under constant assault from pathogens, the faster-acting innate immune system tends to be the first line of response.

Innate immunity defends against most pathogens by rapid responses coordinated through "innate" receptors that recognize a wide spectrum of conserved pathogenic components. Plants for example and many lower animal species do not possess an adaptive immune system, and rely instead upon their innate immunity. This system, when activated, has a wide array of effector cells and mechanisms, which include several different types of phagocytic cells, which together with the Complement System act to ingest and destroy invading pathogens.

SF-1019, which was developed using enhanced protein-profiling techniques, comprises a series of naturally occurring lipo-peptides extracted from a mammalian source. These peptides have been separated by both filtration and other proprietary selective means.

SF-1019 was initially designed as a wound healing product. However, its hypothesized mechanism of action, as derived from observations arising from both the pre-clinical human studies and animal model trials, indicates that SF-1019 may have a wide range of applications relating to conditions of an inflammatory nature such as Multiple Sclerosis (MS), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Reflex Sympathetic Dystrophy Syndrome (RSD or RSDS) (debilitating pain) and other indications.

IMYN Seeking FDA Approval 20-May-11 11:44 pm
IMMUNOSYN ANNOUNCES THE SUCCESSFUL COMPLETION
OF FIRST PHASE “PROOF OF CONCEPT TRIAL” IN EUROPE
FOR TREATMENT OF DIABETIC ULCERS WITH BIOPHARMECEUTICAL SF-1019

Immunosyn Corporation announced that the first phase of a formal "Proof of Concept Trial" for
the biopharmaceutical SF-1019 has been successfully completed in Europe for treatment of
Diabetic Ulcers.
The Board of Immunosyn was advised as to the success of this important phase of the “Proof of
Concept Trial" by Argyll Biotechnologies, LLC its strategic partner and largest shareholder. Argyll
Biotechnologies is the developer and licensor of SF-1019, for which Immunosyn has been granted
the world-wide rights to market, sell and distribute under an exclusive license agreement.
The primary purpose of the “Proof of Concept Trial" is to further evaluate the safety and efficacy
of SF-1019 in the treatment of Diabetic Ulceration and its effect on Diabetic Polyneuropathy in
Type 1 Diabetes Mellitus by both subcutaneous injection and by topical application.
Regarding the "Proof of Concept Trial,” Professor Angus Dalgleish, MBBS, BSc, MD, FRCP, RACP,
FRCPath, FMedSci, Chief Scientist and Consultant Medical Officer for Argyll Biotechnologies, LLC
stated that, “This first very important phase in the development of SF-1019, which was
undertaken at a European venue, has indicated that SF-1019 promotes wound healing and almost
certainly induces growth factors.” “When systemically delivered, SF-1019 has shown the rapid
resolution of long standing chronic lesions which is very impressive. And the topical application of
SF-1019, while showing promise, in that a 5mm deep wound became closed, needs, as expected,
unlike the subcutaneous method, more short-term development in order to improve the delivery
methodology,” he added.
Clinical Director for Argyll Biotechnologies, David Maizels, MD, MSc, MRCS, LRCP, has also advised
that, “Because of the positive results, which both the independent clinical team and I have
observed during the first phase of the "Proof of Concept Trial" and with the absence of any
adverse side effects, the trial will go forward to the next phase and will be expanded to cover a
wider group of patients.”
It is expected that the next phase will be completed during the first half of 2008 and that largerscale
independently-managed formal Clinical Trials, leading to a licensed product in Europe, will
take place shortly thereafter at a world-renowned specialist wound healing clinic.
“The success of this phase of the trial is yet another substantial milestone in moving toward
approval of SF-1019 in Europe for use with Diabetic Ulcers,” said Stephen D. Ferrone, President
and CEO of Immunosyn. “We feel that beyond whatever the potential revenue might be for
Immunosyn, from possible future approval and sales of SF-1019, is the significant and
compassionate role that SF-1019 could eventually play in filling an unmet need in the arena of
wound healing. According to the International Diabetes Federation (IDF), of the 250 million
people globally who suffer from Diabetes Mellitus one out of six will develop a Diabetic Ulcer. To
put that into perspective, currently, worldwide, one person every 30 seconds has a limb
amputated due to Diabetes, 85% of which are preceded by a Diabetic Ulcer; and, as unbelievable
as it seems, until now there have been no known therapies to remedy this tragic condition,”
concluded Mr. Ferrone (CEO Immunosyn).

http://messages.finance.yahoo.com/Stocks_%28A_to_Z%29/Stocks_I/forumview?bn=123455

**Immune Response - IMYN Shines **
Partial Overview of Immune Response to SF-1019
Upon administration, SF-1019 initiates a rapid change in the proteome which persists for at least 24 hours. Mediators of the immune system (e.g., cytokines) are released in pulses during this period. The significance of some of these mediators and targeted entities are described in part below.

Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a protein secreted by macrophages, T cells, mast cells, endothelial cells and fibroblasts. (Borrello and Pardoll 2002)

Interleukin-6 (IL-6) is a cytokine which can be secreted by T cells and macrophages to stimulate immune response to trauma, especially burns or other tissue damage. In terms of host response to a foreign pathogen, IL-6 has been shown to be required for resistance against the bacterium. (Kayama, Yoshida et al. 1997)

Interleukin 12 (IL-12) is an interleukin that is naturally produced by macrophages and human B-lymphoblastoid cells (NC-37) in response to antigenic stimulation. IL-12 is involved in the differentiation of naïve T cells into Th1 Cells, which is important in resistance against pathogens. It is known as a T cell stimulating factor, which can stimulate the growth and function of T cells. It stimulates the production of interferon-gamma (IFN-?) and tumor necrosis factor-alpha (TNF-a) from T and natural killer (NK) cells, and reduces IL-4 mediated suppression of IFN-?. T cells which produce IL-12 have a coreceptor, CD30, which is associated with IL-12 activity. IL-12 plays an important role in the activities of NK cells and T lymphocytes. IL-12 mediates enhancement of the cytotoxic activity of NK cells and CD8+ cytotoxic T lymphocytes. There also seems to be a link between IL-2 and the signal transduction of IL-12 in NK cells. IL-2 stimulates the expression of two IL-12 receptors, IL-12R-ß1 and IL-12R-ß2, maintaining the expression of a critical protein involved in IL-12 signaling in NK cells. Enhanced functional response is demonstrated by IFN-? production and killing target cells. (Watford, Moriguchi et al. 2003)

TNF-a Tumor necrosis factor (TNF, cachexin or cachectin and formally known as tumor necrosis factor-alpha) is a cytokine involved in systemic inflammation and is a member of a group of cytokines that all stimulate the acute phase reaction. (Lorenz and Kalden 2002)

Interferon-gamma (IFN-?) is a dimerized soluble cytokine that is the only member of the type II class of interferons. This interferon was originally called macrophage-activating factor. (Boehm, Klamp et al. 1997)

T cells belong to a group of white blood cells known as lymphocytes and play a central role in cell-mediated immunity. They can be distinguished from other lymphocyte types, such as B cells and NK cells by the presence of a special receptor on their cell surface that is called the T cell receptor (TCR). The abbreviation "T", in T cell, stands for thymus since it is the principal organ for their development. (Croft 2003)
Natural killer (NK) cells are a form of cytotoxic lymphocyte which constitutes a major component of the innate immune system. NK cells play a major role in the host-rejection of both tumors and virally infected cells. They were named "natural killer" because of the initial notion that they do not require activation in order to kill cells which are "missing self" recognition ("missing-self" recognition is a term used to describe cells with low levels of MHC (major histocompatibility complex) class I cell surface marker molecules — a situation which could arise due to viral infection, or in tumors under strong selection pressure of T cells. (Lucas, Schachterle et al. 2007)

Approval for Treatment, Marketing and Distribution in Malaysia

Immunosyn Corporation is currently marketing, distribution and patient treatment approval has been granted by the Ministry of Health Malaysia for SF-1019 in the Private Pay Heath Sector in Malaysia. The marketing name for SF-1019 in Malaysia will be R-1818. Argyll Biotechnologies, LLC, the licensor of SF-1019, Immunosyn?s strategic partner and its largest shareholder, has notified Immunosyn that the Ministry of Health Malaysia has approved the importation, marketing and distribution of SF-1019 in the Private Pay Health Sector throughout Malaysia for the treatment of Diabetic Mellitus, Diabetic Neuropathy, Diabetic Ulcers as well as other Chronic Inflammatory and Degenerative Diseases. The Ministry of Health has also given approval for treating physicians in Malaysia to prescribe and export SF-1019 to patients residing outside of Malaysia. ?Today marks an important chapter in our company?s entrance into the global markets and we are looking forward to commercially launching SF-1019,? said Stephen D. Ferrone, President and CEO of Immunosyn. ?Malaysia is the first country to grant regulatory marketing, treatment and distribution approval of SF-1019,? Ferrone added, ?Immunosyn hopes to make Malaysia a central distribution hub in order for patients worldwide to be able to receive the benefit of SF-1019.? Argyll Biotech has worked for several years on developing the manufacturing processes, protocols, safety procedures and guidelines for SF-1019. Immunosyn, together with Argyll Biotech, is working to finalize Distribution Management and Information Component Systems that will be implemented to define protocols to assure patient safety and regulatory compliance in Malaysia as well as throughout the world prior to treatment commencing. In addition, Argyll Biotech will apply for an import license from Malaysian authorities. These steps are expected to be completed during the fourth quarter of 2008. Argyll Biotech has advised Immunosyn that they plan to continue the process to obtain full regulatory approvals for the marketing of SF-1019 throughout Asia as well as in Europe and then the U.S. ?The healthcare spending of Malaysians is incredibly high, reflecting the trend of Malaysians towards a healthy lifestyle,? stated Douglas A. McClain, Jr., Chairman of the Board and CFO of Immunosyn. ?This is an exciting early-stage development as this puts revenue producing capabilities within short-term range for the company.? SF-1019 is a compound that was developed from extensive research into Biological Response Modifiers. This research suggests that SF-1019 has the potential to affect a number of clinical conditions including complications from Diabetes Mellitus such as Diabetic Neuropathy (DN) and diabetic ulcers (DU), auto-immune disorders such as Multiple Sclerosis (MS) and neurological disorders. Results from a recent study undertaken in Europe to evaluate the safety and efficacy of SF-1019 in the treatment of Diabetic Ulceration and its effect on Diabetic Polyneuropathy in Type 1 Diabetes Mellitus suggest that SF-1019 promotes wound healing and induces growth factors. Globally, according to Diabetes Atlas, third edition ? International Diabetes Federation, 2006 and www.diabetes.niddk.nih.gov: Approximately 246 million people have Diabetes Mellitus Estimated 50% (143 million) have Diabetic Neuropathy (DN) 1 in 6 (41 million) will develop a foot ulcer Malaysia has a population of just over 25,000,000 people. According to the Ministry of Health Malaysia, in 2008 nearly 17% of the general population of Malaysia had Diabetes Mellitus. The Ministry states in its

RESEARCH with STRONG RECOMMENDATIONS

Immunosyn comprises the platform technology for what many believes may lead to a new, world class series of Biological Response Modifiers (BMRs) developed from mammalian serum. This technology represents a cutting edge scientific breakthrough, utilizing some of the many complex compounds and cells generated by the immune systems of living animals in response to viral, bacterial and other stress challenges. The current research medications for a number of neurological conditions, as derived has demonstrated their ability to create a wide variety of immune responses by targeting both the innate and adaptive immune systems simultaneously.

The basic technology and mechanism of action was originally discovered by Argyll Biotechnologies’ principal investigator, Professor Kenneth Willeford, of Mississippi State University. Claims in a key patent application, which encompass the molecule and names Dr. Willeford as an inventor, have recently been allowed and are expected to issue. Additional patent protection has also been applied for concerning the manufacturing processes and chemical variations for Immunosyn.

In various pre-clinical human studies, performed under either informed consent (EU) or compassionate waiver (U.S.), over 1000 subcutaneous 1.5 ml doses have been administered to over 80 patients, with no major adverse events being reported over a period in excess of 18 months. Treatment with SF-1019 would appear to induce an immunomodulatory cascade, which could explain the therapeutic effects. Patients who were suffering from a range of conditions of the nervous and immune systems, have reported a rapid reduction of their symptoms in as little as 5-6 minutes. Since some of the improvements occur too quickly for known anti-inflammatory pathways, it is possible that SF-1019 possesses neuro restorative properties via a channel blocking process. Moreover, increased levels of cytokine expression were also observed. The immunological profile of patients with inflammatory conditions who have received treatment appear to have had their cytokine profiles convert from a TH-1 to a TH-2 status; in other words, from a hyper-stimulated and pro-inflammatory to a largely anti-inflammatory condition. This would result in the reduction of inflammation mediated tissue damage in patients with such conditions.

Science Behind It
SF-1019 has also been shown to function
as a vaccine adjuvant for antigens
of both viral and bacterial origin

SF-1019 comprises the platform technology for what Argyll Biotechnologies believes may lead to a new, world class series of Biological Response Modifiers (BMRs) developed from mammalian serum. Argyll Biotechnologies feels this technology represents a cutting edge scientific breakthrough, utilizing some of the many complex compounds and cells generated by the immune systems of living animals in response to viral, bacterial and other stress challenges. The current research medications for a number of neurological conditions, as derived from SF-1019, have demonstrated their ability to create a wide variety of immune responses by targeting both the innate and adaptive immune systems simultaneously.

The basic technology and mechanism of action of SF-1019 were originally discovered by Argyll Biotechnologies’ principal investigator, Professor Kenneth Willeford, of Mississippi State University. Claims in a key patent application, which encompass the SF-1019 molecule and names Dr. Willeford as an inventor, have recently been allowed and are expected to issue. Additional patent protection has also been applied for concerning the manufacturing processes and chemical variations of SF-1019.

SF-1019, as disclosed and described in Argyll Biotechnologies’ published patent applications, comprises a group of novel lipo-peptides which have no direct antimicrobial activity when screened against a variety of gram positive and gram negative bacteria. Nevertheless, in pre-clinical human studies as well as animal studies, SF-1019 demonstrates an ability to abate microbial pathogenesis as presented in Salmonella typhimurium mouse and Pasteurella multocida avian models while also appearing to abate viral pathogenesis as presented in a canine parvovirus study. SF-1019 has also been shown to function as a vaccine adjuvant for antigens of both viral and bacterial origin. In veterinary clinical field trials, it has been shown to be effective against bovine respiratory disease complex (shipping fever), canine parvo viral enteritis, equine West Nile Viral encephalitis, and equine respiratory disease.

Following an initial infection, the adaptive immune system may take days or weeks to react. However as most organisms are under constant assault from pathogens, the faster-acting innate immune system tends to be the first line of response.

Innate immunity defends against most pathogens by rapid responses coordinated through "innate" receptors that recognize a wide spectrum of conserved pathogenic components. Plants for example and many lower animal species do not possess an adaptive immune system, and rely instead upon their innate immunity. This system, when activated, has a wide array of effector cells and mechanisms, which include several different types of phagocytic cells, which together with the Complement System act to ingest and destroy invading pathogens.

SF-1019, which was developed using enhanced protein-profiling techniques, comprises a series of naturally occurring lipo-peptides extracted from a mammalian source. These peptides have been separated by both filtration and other proprietary selective means.

SF-1019 was initially designed as a wound healing product. However, its hypothesized mechanism of action, as derived from observations arising from both the pre-clinical human studies and animal model trials, indicates that SF-1019 may have a wide range of applications relating to conditions of an inflammatory nature such as Multiple Sclerosis (MS), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Reflex Sympathetic Dystrophy Syndrome (RSD or RSDS) (debilitating pain) and other indications.

Recent Study
-----------------------------------------------------------------------
In no case was there a negative showing as to a safety issue and in most there was a measurable improvement in a clinical condition SF-1019 has shown great promise over a wide range of applications relating to conditions of an inflammatory nature such as Multiple Sclerosis (MS), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Reflex Sympathetic Dystrophy Syndrome (RSD or RSDS).

Following a series of toxicity studies in animals, SF-1019 demonstrated a positive safety profile.

Recently, in one of Argyll Biotechnologies’ pre-clinical human studies, a small number of patients were provided with SF-1019 treatments under informed consent (EU) and a compassionate waiver program (US). Information collected from this study extended over a ten month period and included a brief record of clinical progress (if any), together with dose ranging and toxicity data.

A standard battery of blood tests were undertaken pre-treatment and at four, eight and twelve week intervals. In no case was there a negative showing as to a safety issue and in most there was a measurable improvement in a clinical condition. For example, there were no apparent biochemical changes in the blood analysis and no adverse reactions recorded in this group.

Many of the patients who participated in this program continue to receive compassionate treatments of SF-1019.

How much longer until FDA approval?

Partial Overview of Immune Response to SF-1019
Upon administration, SF-1019 initiates a rapid change in the proteome which persists for at least 24 hours. Mediators of the immune system (e.g., cytokines) are released in pulses during this period. The significance of some of these mediators and targeted entities are described in part below.


--------------------------------------------------------------------------------

Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a protein secreted by macrophages, T cells, mast cells, endothelial cells and fibroblasts.





--------------------------------------------------------------------------------

Interleukin-6 (IL-6) is a cytokine which can be secreted by T cells and macrophages to stimulate immune response to trauma, especially burns or other tissue damage. In terms of host response to a foreign pathogen, IL-6 has been shown to be required for resistance against the bacterium.


--------------------------------------------------------------------------------

Interleukin 12 (IL-12) is an interleukin that is naturally produced by macrophages and human B-lymphoblastoid cells (NC-37) in response to antigenic stimulation. IL-12 is involved in the differentiation of naïve T cells into Th1 Cells, which is important in resistance against pathogens. It is known as a T cell stimulating factor, which can stimulate the growth and function of T cells. It stimulates the production of interferon-gamma (IFN-?) and tumor necrosis factor-alpha (TNF-a) from T and natural killer (NK) cells, and reduces IL-4 mediated suppression of IFN-?. T cells which produce IL-12 have a coreceptor, CD30, which is associated with IL-12 activity. IL-12 plays an important role in the activities of NK cells and T lymphocytes. IL-12 mediates enhancement of the cytotoxic activity of NK cells and CD8+ cytotoxic T lymphocytes. There also seems to be a link between IL-2 and the signal transduction of IL-12 in NK cells. IL-2 stimulates the expression of two IL-12 receptors, IL-12R-ß1 and IL-12R-ß2, maintaining the expression of a critical protein involved in IL-12 signaling in NK cells. Enhanced functional response is demonstrated by IFN-? production and killing target cells.

--------------------------------------------------------------------------------

TNF-a Tumor necrosis factor (TNF, cachexin or cachectin and formally known as tumor necrosis factor-alpha) is a cytokine involved in systemic inflammation and is a member of a group of cytokines that all stimulate the acute phase reaction.


--------------------------------------------------------------------------------

Interferon-gamma (IFN-?) is a dimerized soluble cytokine that is the only member of the type II class of interferons. This interferon was originally called macrophage-activating factor.



--------------------------------------------------------------------------------

T cells belong to a group of white blood cells known as lymphocytes and play a central role in cell-mediated immunity. They can be distinguished from other lymphocyte types, such as B cells and NK cells by the presence of a special receptor on their cell surface that is called the T cell receptor (TCR). The abbreviation "T", in T cell, stands for thymus since it is the principal organ for their development.

--------------------------------------------------------------------------------

Natural killer (NK) cells are a form of cytotoxic lymphocyte which constitutes a major component of the innate immune system. NK cells play a major role in the host-rejection of both tumors and virally infected cells. They were named "natural killer" because of the initial notion that they do not require activation in order to kill cells which are "missing self" recognition ("missing-self" recognition is a term used to describe cells with low levels of MHC (major histocompatibility complex) class I cell surface marker molecules — a situation which could arise due to viral infection, or in tumors under strong selection pressure of T cells.



CITATIONS
Borrello, I. and D. Pardoll (2002). "GM-CSF-based cellular vaccines: a review of the clinical experience." Cytokine & Growth Factor Reviews 13(2): 185-193.

Kayama, F., T. Yoshida, et al. (1997). "PRO-INFLAMMATORY CYTOKINES AND INTERLEUKIN 6 IN THE RENAL RESPONSE TO BACTERIAL ENDOTOXIN." Cytokine 9(9): 688-695.

Watford, W. T., M. Moriguchi, et al. (2003). "The biology of IL-12: coordinating innate and adaptive immune responses." Cytokine & Growth Factor Reviews 14(5): 361-368.

Lorenz, H.-M. and J. Kalden (2002). "Perspectives for TNF-alpha-targeting therapies." Arthritis Res 4(Suppl 3): S17 - S24.

Boehm, U., T. Klamp, et al. (1997). "CELLULAR RESPONSES TO INTERFERON-Gamma." Annual Review of Immunology 15(1): 749-795.
Croft, M. (2003). "Costimulation of T cells by OX40, 4-1BB, and CD27." Cytokine & Growth Factor Reviews 14(3-4): 265-273.

Lucas, M., W. Schachterle, et al. (2007). "Dendritic Cells Prime Natural Killer Cells by trans-Presenting Interleukin 15." Immunity 26(4): 503-517.

Hi PT,
It appears the share count has not changed. Since it moves on light volume, I believe the low float to be true. This could easily move back to $1.50 with buyers. All the technicals are there. Spread the good word and thank you for your post.

IMYN looks interesting. Has anyone been able to get an updated Share Structure from the Transfer Agent?

EU License Approval Pending

IMYN does have License Approval in Europe for it's Biopharmaceutical Drug - Immunosyn Corporation has approval from the MHRA to import base material and manufacture it's drug for human use in clinical trials. Immunosyn holds the exclusive license for worldwide marketing rights.

The "Medicines and Healthcare products Regulatory Agency," more commonly known as the MHRA, functions in the United Kingdom on behalf of the European Medicines Agency (EMEA) much like the FDA does in the United States. MHRA regulates which drugs are safe and effective for use in humans to treat specific ailments and conditions. The license approvals currently granted by the MHRA include a "Manufacturer's Authorisation -- Investigational Medicinal Products" (MIA (IMP)) as well as "Manufacturer's / Importer's Licence" (MIA) for manufacturing investigational medicinal products for use in humans for phase I, II and III clinical trials. If a company successfully completes these trials it can apply for a full license to distribute throughout the European Union.

"The fact that it has garnered manufacturing and import approval from the MHRA so rapidly is exciting news," says Stephen D. Ferrone, CEO and President of Immunosyn, "as every milestone we achieve in this process brings us that much closer to producing revenue for our shareholders."

"This is another example whereby Immunosyn's shareholders strongly benefit from our unique relationship with our largest shareholder, Argyll Biotechnologies," stated David Criner, CFO of Immunosyn. "Under the terms of our exclusive license agreement, Argyll Biotechnologies is responsible for all regulatory approvals and clinical trials including those required by the MHRA and FDA together with their associated costs."

Under EMEA requirements, in order to obtain approval to manufacture a drug for use in humans, whether for clinical trials or for general use, an approved manufacturer must be able to demonstrate its ability to comply with the rules governing "Good Manufacturing Practice" (GMP) and apply directly to the MHRA for license approval. Following a series of manufacturing "scale-up" studies, Argyll Biotechnologies entered into an agreement with Biozyme Laboratories. As a result of this agreement, Biozyme applied for and received manufacturing and base materials import approval from MHRA for clinical trials for the Immunosyn Corporation.

Research
Reflex Sympathetic Dystrophy Syndrome (RSDS)

What is reflex sympathetic dystrophy?

Reflex sympathetic dystrophy syndrome (RSDS) is a condition that features a group of typical symptoms, including pain (often "burning" type), tenderness, and swelling of an extremity associated with varying degrees of sweating, warmth and/or coolness, flushing, discoloration, and shiny skin.


What causes reflex sympathetic dystrophy?

RSDS is also referred to as "the shoulder-hand syndrome," "causalgia," and "Sudeck's atrophy." The exact mechanism of how RSDS develops is poorly understood. The theories include irritation and abnormal excitation of nervous tissue, leading to abnormal impulses along nerves that affect blood vessels and skin. A variety of events can trigger the condition, including trauma, surgery, heart disease, degenerative arthritis of the neck, stroke or other brain diseases, nerve irritation by entrapment (such as carpal tunnel syndrome) or shingles, shoulder problems, breast cancer, and drugs for tuberculosis and barbiturates. There is no associated event in one-third of patients.


What are the symptoms of reflex sympathetic dystrophy?

The onset of the RSDS symptoms may be rapid on gradual. The condition may not display all features. It has been bilateral in up to half of the patients. There are several stages:

* Acute: (three to six months) burning, flushing, blanching, sweating, swelling, pain, and tenderness. This stage can show early x- ray changes of patchy bone thinning.


* Dystrophic: (three to six months) early skin changes of shiny, thickened skin and contracture with persistent pain, but diminished swelling and flushing.


* Atrophic: (may be long-standing) loss of motion and function of the involved hand or foot with contracture (flexed scarring process), thinning of the fatty layers under the skin. X-ray can show significant osteoporosis.



Chronic inflammatory demyelinating polyneuropathy (CIDP) is an acquired immune-mediated inflammatory disorder of the peripheral nervous system but often can have central nervous system involvement. The disorder is sometimes called chronic relapsing polyneuropathy. CIDP is closely related to Guillain-Barre syndrome and it is considered the chronic counterpart of that acute disease.

The pathologic hallmark of the disease is loss of the myelin sheath (the fatty covering that wraps around and protects nerve fibers) of the peripheral nerves.

Chronic inflammatory demyelinating polyneuropathy is disease believed to be due to immune cells, cells which normally protect the body from foreign infection, but here begin incorrectly attacking the nerves in the body instead. As a result, the affected nerves fail to respond, or respond only weakly, to stimuli causing numbing, tingling, pain, progressive muscle weakness, loss of deep tendon reflexes (areflexia), fatigue, and abnormal sensations. The likelihood of progression of the disease is high.

CIDP is under-recognized and under-treated due to its heterogeneous presentation (both clinical and electrophysiological) and the limitations of clinical, serologic, and electrophysiologic diagnostic criteria.

IMYN is a great find in penny land, thanks for the heads up and the info! I can't believe this current pps and had to jump in myself. This stock has no where to go but up for the long holders. As a neurologist, this looks extremely promising, as there are limited treatments for these disorders...

IMYN

Technology Breakthrough

Science Behind SF-1019
SF-1019 has also been shown to function
as a vaccine adjuvant for antigens
of both viral and bacterial origin

SF-1019 comprises the platform technology for what Argyll Biotechnologies believes may lead to a new, world class series of Biological Response Modifiers (BMRs) developed from mammalian serum. Argyll Biotechnologies feels this technology represents a cutting edge scientific breakthrough, utilizing some of the many complex compounds and cells generated by the immune systems of living animals in response to viral, bacterial and other stress challenges. The current research medications for a number of neurological conditions, as derived from SF-1019, have demonstrated their ability to create a wide variety of immune responses by targeting both the innate and adaptive immune systems simultaneously.

The basic technology and mechanism of action of SF-1019 were originally discovered by Argyll Biotechnologies’ principal investigator, Professor Kenneth Willeford, of Mississippi State University. Claims in a key patent application, which encompass the SF-1019 molecule and names Dr. Willeford as an inventor, have recently been allowed and are expected to issue. Additional patent protection has also been applied for concerning the manufacturing processes and chemical variations of SF-1019.

SF-1019, as disclosed and described in Argyll Biotechnologies’ published patent applications, comprises a group of novel lipo-peptides which have no direct antimicrobial activity when screened against a variety of gram positive and gram negative bacteria. Nevertheless, in pre-clinical human studies as well as animal studies, SF-1019 demonstrates an ability to abate microbial pathogenesis as presented in Salmonella typhimurium mouse and Pasteurella multocida avian models while also appearing to abate viral pathogenesis as presented in a canine parvovirus study. SF-1019 has also been shown to function as a vaccine adjuvant for antigens of both viral and bacterial origin. In veterinary clinical field trials, it has been shown to be effective against bovine respiratory disease complex (shipping fever), canine parvo viral enteritis, equine West Nile Viral encephalitis, and equine respiratory disease.

Following an initial infection, the adaptive immune system may take days or weeks to react. However as most organisms are under constant assault from pathogens, the faster-acting innate immune system tends to be the first line of response.

Innate immunity defends against most pathogens by rapid responses coordinated through "innate" receptors that recognize a wide spectrum of conserved pathogenic components. Plants for example and many lower animal species do not possess an adaptive immune system, and rely instead upon their innate immunity. This system, when activated, has a wide array of effector cells and mechanisms, which include several different types of phagocytic cells, which together with the Complement System act to ingest and destroy invading pathogens.

SF-1019, which was developed using enhanced protein-profiling techniques, comprises a series of naturally occurring lipo-peptides extracted from a mammalian source. These peptides have been separated by both filtration and other proprietary selective means.

SF-1019 was initially designed as a wound healing product. However, its hypothesized mechanism of action, as derived from observations arising from both the pre-clinical human studies and animal model trials, indicates that SF-1019 may have a wide range of applications relating to conditions of an inflammatory nature such as Multiple Sclerosis (MS), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Reflex Sympathetic Dystrophy Syndrome (RSD or RSDS) (debilitating pain) and other indications.

$$$ Seeking FDA Approval $$$

IMMUNOSYN ANNOUNCES THE SUCCESSFUL COMPLETION
OF FIRST PHASE “PROOF OF CONCEPT TRIAL” IN EUROPE
FOR TREATMENT OF DIABETIC ULCERS WITH BIOPHARMECEUTICAL SF-1019

Immunosyn Corporation announced that the first phase of a formal "Proof of Concept Trial" for
the biopharmaceutical SF-1019 has been successfully completed in Europe for treatment of
Diabetic Ulcers.
The Board of Immunosyn was advised as to the success of this important phase of the “Proof of
Concept Trial" by Argyll Biotechnologies, LLC its strategic partner and largest shareholder. Argyll
Biotechnologies is the developer and licensor of SF-1019, for which Immunosyn has been granted
the world-wide rights to market, sell and distribute under an exclusive license agreement.
The primary purpose of the “Proof of Concept Trial" is to further evaluate the safety and efficacy
of SF-1019 in the treatment of Diabetic Ulceration and its effect on Diabetic Polyneuropathy in
Type 1 Diabetes Mellitus by both subcutaneous injection and by topical application.
Regarding the "Proof of Concept Trial,” Professor Angus Dalgleish, MBBS, BSc, MD, FRCP, RACP,
FRCPath, FMedSci, Chief Scientist and Consultant Medical Officer for Argyll Biotechnologies, LLC
stated that, “This first very important phase in the development of SF-1019, which was
undertaken at a European venue, has indicated that SF-1019 promotes wound healing and almost
certainly induces growth factors.” “When systemically delivered, SF-1019 has shown the rapid
resolution of long standing chronic lesions which is very impressive. And the topical application of
SF-1019, while showing promise, in that a 5mm deep wound became closed, needs, as expected,
unlike the subcutaneous method, more short-term development in order to improve the delivery
methodology,” he added.
Clinical Director for Argyll Biotechnologies, David Maizels, MD, MSc, MRCS, LRCP, has also advised
that, “Because of the positive results, which both the independent clinical team and I have
observed during the first phase of the "Proof of Concept Trial" and with the absence of any
adverse side effects, the trial will go forward to the next phase and will be expanded to cover a
wider group of patients.”
It is expected that the next phase will be completed during the first half of 2008 and that largerscale
independently-managed formal Clinical Trials, leading to a licensed product in Europe, will
take place shortly thereafter at a world-renowned specialist wound healing clinic.
“The success of this phase of the trial is yet another substantial milestone in moving toward
approval of SF-1019 in Europe for use with Diabetic Ulcers,” said Stephen D. Ferrone, President
and CEO of Immunosyn. “We feel that beyond whatever the potential revenue might be for
Immunosyn, from possible future approval and sales of SF-1019, is the significant and
compassionate role that SF-1019 could eventually play in filling an unmet need in the arena of
wound healing. According to the International Diabetes Federation (IDF), of the 250 million
people globally who suffer from Diabetes Mellitus one out of six will develop a Diabetic Ulcer. To
put that into perspective, currently, worldwide, one person every 30 seconds has a limb
amputated due to Diabetes, 85% of which are preceded by a Diabetic Ulcer; and, as unbelievable
as it seems, until now there have been no known therapies to remedy this tragic condition,”
concluded Mr. Ferrone.

THE NEXT BIG DRUG BREAKTHROUGH!

“Regulatory approval processes for IMYN have been initiated in several countries. Additionally, in both the US and Europe preparations for clinical trials are underway. Research indicates that it has the potential to affect neurological disorders such as Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Reflex Sympathetic Dystrophy Syndrome (RSD or RSDS), autoimmune disorders such as Multiple Sclerosis (MS), and a number of clinical conditions including complications from Diabetic Mellitus such as Diabetic Neuropathy (DN) and diabetic ulcers (DU).”

“We have a drug that is fully developed, which our Scientific Advisory Board believes has demonstrated safety and efficacy for indications for which we hope the treatment will be approved. We are in the marketplace raising awareness and are cognizant of the need to set up a viable distribution system. We are at the cutting-edge of where drug development and therapies are today. The two Orphan Diseases for which Argyll Biotechnologies plans to seek FDA approval in the US are Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Reflex Sympathetic Dystrophy (RSD or RSDS). However, the overall target market is potentially broader. It could include indications such as Multiple Sclerosis (MS), from which an estimated 2.5 million people suffer worldwide. There is also the potential to be used in treating complications from Diabetic Mellitus such as Diabetic Neuropathy (DN) and diabetic ulcers (DU). Worldwide, approximately 246 million people have Diabetes Mellitus, of those, 1 in 6 will develop a foot ulcers and an estimated 50% have a Diabetic Neuropathy (DN). Therefore, there is certainly a large potential market. From a business standpoint as well as a humanitarian standpoint, we feel there is great potential.”
- Stephen D. Ferrone, CEO

Strong Buy

Immunosyn comprises the platform technology for what many believes may lead to a new, world class series of Biological Response Modifiers (BMRs) developed from mammalian serum. This technology represents a cutting edge scientific breakthrough, utilizing some of the many complex compounds and cells generated by the immune systems of living animals in response to viral, bacterial and other stress challenges. The current research medications for a number of neurological conditions, as derived has demonstrated their ability to create a wide variety of immune responses by targeting both the innate and adaptive immune systems simultaneously.

The basic technology and mechanism of action was originally discovered by Argyll Biotechnologies’ principal investigator, Professor Kenneth Willeford, of Mississippi State University. Claims in a key patent application, which encompass the molecule and names Dr. Willeford as an inventor, have recently been allowed and are expected to issue. Additional patent protection has also been applied for concerning the manufacturing processes and chemical variations for Immunosyn.

In various pre-clinical human studies, performed under either informed consent (EU) or compassionate waiver (U.S.), over 1000 subcutaneous 1.5 ml doses have been administered to over 80 patients, with no major adverse events being reported over a period in excess of 18 months. Treatment with SF-1019 would appear to induce an immunomodulatory cascade, which could explain the therapeutic effects. Patients who were suffering from a range of conditions of the nervous and immune systems, have reported a rapid reduction of their symptoms in as little as 5-6 minutes. Since some of the improvements occur too quickly for known anti-inflammatory pathways, it is possible that SF-1019 possesses neuro restorative properties via a channel blocking process. Moreover, increased levels of cytokine expression were also observed. The immunological profile of patients with inflammatory conditions who have received treatment appear to have had their cytokine profiles convert from a TH-1 to a TH-2 status; in other words, from a hyper-stimulated and pro-inflammatory to a largely anti-inflammatory condition. This would result in the reduction of inflammation mediated tissue damage in patients with such conditions.

REAL PRODUCT for REAL PEOPLE!

Immunosyn has a product that is helping many people such as Lisa; who has blog explaining how it is changing her life. The link is provided below. Her last entry was in March of 2011. Once FDA approves the drug, she will be able to afford it better on a daily basis. Let's Go IMYN!

"My dream is still using this vaccine, it worked better than any MS treatment I ever tried before"

"I know for a fact my MS would be under control with the SF1019 vaccine"

"I had a great experience with the vaccine, it gave me lots of energy which I sorely miss"

"My experience was very positive, no side effects"

"I used the SF1019 Immunosyn vaccine for just 13 months but did feel much more energy and my legs felt stronger"

http://www.msrebel.com/my%20immunosyn%20SF1019%20vaccine%20experience.htm

IMYN - FDA Approval Coming!!!

Perfect Timing as Stock is at all time lows too. Small Float! This will run back to a $1.50 in no time. Get it now. Good Luck to all.

“Regulatory approval processes for IMYN have been initiated in several countries. Additionally, in both the US and Europe preparations for clinical trials are underway. Research indicates that it has the potential to affect neurological disorders such as Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Reflex Sympathetic Dystrophy Syndrome (RSD or RSDS), autoimmune disorders such as Multiple Sclerosis (MS), and a number of clinical conditions including complications from Diabetic Mellitus such as Diabetic Neuropathy (DN) and diabetic ulcers (DU).”

“We have a drug that is fully developed, which our Scientific Advisory Board believes has demonstrated safety and efficacy for indications for which we hope the treatment will be approved. We are in the marketplace raising awareness and are cognizant of the need to set up a viable distribution system. We are at the cutting-edge of where drug development and therapies are today. The two Orphan Diseases for which Argyll Biotechnologies plans to seek FDA approval in the US are Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Reflex Sympathetic Dystrophy (RSD or RSDS). However, the overall target market is potentially broader. It could include indications such as Multiple Sclerosis (MS), from which an estimated 2.5 million people suffer worldwide. There is also the potential to be used in treating complications from Diabetic Mellitus such as Diabetic Neuropathy (DN) and diabetic ulcers (DU). Worldwide, approximately 246 million people have Diabetes Mellitus, of those, 1 in 6 will develop a foot ulcers and an estimated 50% have a Diabetic Neuropathy (DN). Therefore, there is certainly a large potential market. From a business standpoint as well as a humanitarian standpoint, we feel there is great potential.”
- Stephen D. Ferrone, CEO

Anyone else in on this?

25k buys @ .06

Slow n steady. Looks good.

no volume on shitty markets. gonna keep holding

in at .058

Don't know, but boy it sure does look good. )

why is IMYN up

here is a interesting link

http://www.accessdata.fda.gov/scripts/Im...

There are lots of reasons not too. The person behind the promotion is a real dirt bag. He posted on Ihub undisclosed for along while. Once the BCSC named him as part of a stock he was pushing and I exposed him he disappeared and has never posted again under the nick.
He was nailed by the SEC in 2001 for a diet pill scam even. Terrible situation here with numerous federal agencies sniffing around..... Isn't that right midtownmurphy?

Here are some interesting links to mull over to help you make your own mind up to whether to invest or not I did not because off these reasons "below"!!

http://www.proventus.org.uk/Denise%20Campbell%20v%20Immunosyn%20et%20al..pdf

http://www.proventus.org.uk/2009.11.24%20IMMYNOSYN_ARGYLL_MICELI_MCCLAIN_LAWSUIT_ROBERT%20ALBERGO_DAVID%20IRWIN.pdf

http://www.proventus.org.uk/1999.08.26%20People%20vs%20James%20T%20Miceli.pdf

http://yahoo.brand.edgar-online.com/displayfilinginfo.aspx?FilingID=6945484-3965-24953&type=sect&TabIndex=2&companyid=720945&ppu=%252fDefault.aspx%253fcompanyid%253d720945%2526amp%253bformtypeID%253d13

http://www.youtube.com/v/QxH5PcEeZfc

http://www.contactmusic.com/new/xmlfeed.nsf/story/osmond-discovers-miracle-ms-drug

any thing you don't under stand on what going on with these people post a reply and I will
indever to help you,remember I only found out all this by research.

I TOLD YOU SO!!!!!!

http://immunosyn.wordpress.com/

From her myspace site, it gives this website:

http://www.parallelmarketing.net/

parallel marketing services

So who's "PMS Girl"?

IMYN quarterly

http://ih.advfn.com/p.php?pid=nmona&cb=1243622990&article=37780909&symbol=NB%5EIMYN

IMYN 10Q 05/12/09


http://ih.advfn.com/p.php?pid=nmona&cb=1243622990&article=37689430&symbol=NB%5EIMYN

Parallel Marketing Services

http://www.myspace.com/parallelpms

My my. Did you accidentally leave out the stuff about the SEC investigation when you were "fixing up" the IBox? I think it very definitely belongs there:

Item 8.01. Other Events.

Immunosyn Corporation (the “Company” or “Immunosyn”) reports that pursuant to subpoenas issued by the Securities and Exchange Commission (“SEC”) to affiliates of Argyll Biotechnologies LLC, the Company’s largest shareholder (“Argyll Biotech”), on March 30, 2006 and to Immunosyn on December 15, 2006 in a proceeding captioned In The Matter of The Argyll Group, LLC, the Company and its affiliates have been asked to produce all documents concerning a wide variety of topics including many related directly to the Company. Pursuant to a third subpoena dated December 15, 2006 issued by the SEC to the Company, the Company has been asked to produce documents concerning private placements of the Company’s stock and other matters disclosed in the Company’s SEC filings. The Company and Argyll Biotech’s affiliates produced documents responsive to these subpoenas, completing their responses in early August 2007. Neither Immunosyn nor any of Argyll Biotech’s affiliates had any further communication with the SEC regarding the subpoenas from January 2007 until recently. On or about March 17, 2009, representatives of both Immunosyn and Argyll Biotech became aware that they had received additional subpoenas from the SEC on or about March 6, 2009. The Company intends to comply with the subpoena directed to it as quickly as possible.

http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=6221748

LA JOLLA, Calif., Mar 20, 2009 (BUSINESS WIRE) -- Immunosyn Corporation
(OTCBB:IMYN) has announced that Dr. Myron Wentz has resigned from the Board of
Directors of Immunosyn Corporation for personal reasons.

Dr. Wentz is increasing his focus on his humanitarian and charitable endeavors,
recently founding the Wentz Medical Centre and Laboratory in Uganda and the
Wentz Medical Centre in Cambodia to serve children in those countries orphaned
by diseases such as malaria and HIV.

Dr. Myron Wentz states that, "I continue my interest in Immunosyn's efforts
through Argyll Biotechnologies, LLC to seek approvals and commercialization of
SF-1019. I plan to use the resources available to me to assist in any
appropriate way so that SF-1019 can eventually be used at Sanoviv Medical
Institute."

Dr. Wentz founded Sanoviv with a vision to heal the world of debilitating
disease. In June 2007, Dr. Wentz was a recipient of the Albert Einstein Award
for Outstanding Achievement in the Life Sciences. In 2006, Dr. Wentz was a
recipient of the Children's Champion Award by Children's Hunger Fund, for which
he travels worldwide as a medical missionary.

"We appreciated Dr. Wentz's expertise during his time on the Board of Directors
of Immunosyn and look forward to working with him in the future," commented
Stephen D. Ferrone, CEO and President of Immunosyn Corporation.

About Immunosyn Corporation

La Jolla, CA-headquartered Immunosyn Corporation (OTCBB:IMYN) plans to market
and distribute life enhancing therapeutics. Currently, the company has exclusive
worldwide rights from its largest shareholder, Argyll Biotechnologies, LLC, to
market, sell and distribute SF-1019, a compound that was developed from
extensive research into Biological Response Modifiers (BRMs). Argyll
Biotechnologies, LLC has initiated the process for regulatory approval of
SF-1019 in several countries and preparations for clinical trials are underway
in both the US and Europe. Research suggests that SF-1019 has the potential to
affect a number of clinical conditions including auto-immune disorders such as
Multiple Sclerosis (MS), neurological disorders such as Chronic Inflammatory
Demyelinating Polyneuropathy (CIDP) and Reflex Sympathetic Dystrophy Syndrome
(RSD or RSDS) and complications from Diabetic Mellitus such Diabetic Neuropathy
(DN) and Diabetic Ulcers (DU).

SOURCE: Immunosyn Corporation



CONTACT:
The Blaine Group
Devon Blaine, 310-360-1499
310-360-1498 (FAX)
blaine@blainegroupinc.com

News for 'IMYN' - (Immunosyn Corporation Announces 2008 Results)


LA JOLLA, Calif., Mar 19, 2009 (BUSINESS WIRE) -- Immunosyn Corporation
(OTCBB:IMYN), a biotechnology firm that has obtained exclusive worldwide
marketing, sales and distribution rights to the biopharmaceutical SF-1019, has
announced its results for the fiscal year ending December 31, 2008.

The company incurred $1,045,013 in general and administrative expenses and
$61,326 in interest expense in fiscal year 2008 for a Net Loss of $1,106,339.
During 2007, the company incurred $647,000 in general and administrative
expenses and $26,000 in interest expense for a Net Loss of $672,837. Immunosyn
has no revenue to date as its affiliate, Argyll Biotechnologies, LLC, has not
yet obtained governmental and regulatory approval to permit the marketing and
sale of SF-1019. The Company had $893,663 of advances from affiliates and had
$320,352 of accounts payable at December 31, 2008. The Company had $640,708 of
advances from affiliates and had $151,693 of accounts payable at December 31,
2007.

"We were able to control costs in 2008 and appreciated the advances from
affiliates," noted Stephen Ferrone, Immunosyn's CEO. "We are striving for
financial efficiency in the execution of marketing and distribution strategy
when approvals fo r SF-1019 are obtained by Argyll Biotechnologies, LLC," added
Ferrone.

About Immunosyn Corporation

La Jolla, CA-headquartered Immunosyn Corporation (OTCBB:IMYN) plans to market
and distribute life enhancing therapeutics. Currently, the company has exclusive
worldwide rights from its largest shareholder, Argyll Biotechnologies, LLC, to
market, sell and distribute SF-1019, a compound that was developed from
extensive research into Biological Response Modifiers (BRMs). Argyll
Biotechnologies, LLC has initiated efforts to seek regulatory approval of
SF-1019 in several countries and to plan for clinical trials in both the US and
Europe. Research suggests that SF-1019 has the potential to affect a number of
clinical conditions including complications from Diabetic Mellitus such as
Diabetic Neuropathy (DN) and diabetic ulcers (DU), auto-immune disorders such as
Multiple Sclerosis (MS) and neurological disorders such as Chronic Inflammatory
Demyelinating Polyneuropathy (CIDP) and Reflex Sympathetic Dystrophy Syndrome
(RSD or RSDS).

The above news release contains forward-looking statements. These statements are
based on assumptions that management believes are reasonable based on currently
available information, and include statements regarding the intent, belief or
current expectations of the Company and its management. Prospective investors
are cautioned that any such forward-looking statements are not guarantees of
future performance, and are subject to a wide range of business risks, external
factors and uncertainties. Actual results may differ materially from those
indicated by such forward-looking statements. For additional information, please
consult the Company's most recent public filings and Annual Report on Form 10-K
for its most recent fiscal year. The Company assumes no obligation to update the
information contained in this press release, whether as a result of new
information, future events or otherwise.

SOU RCE: Immunosyn Corporation



CONTACT:
The Blaine Group
Devon Blaine, 310-360-1499
310-360-1498 (FAX)
blaine@blainegroupinc.com




Copyright Business Wire 2009

-0-




KEYWORD: United States

North America

California

INDUSTRY KEYWORD: Health

Biotechnology

Pharmaceutical

Professional Services

Finance

SUBJECT CODE: Earnings